Reumatologia clinica最新文献

{"title":"Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis","authors":"José María Álvaro-Gracia Álvaro ,&nbsp;Petra Díaz del Campo Fontecha ,&nbsp;José Luis Andréu Sánchez ,&nbsp;Alejandro Balsa Criado ,&nbsp;Rafael Cáliz Cáliz ,&nbsp;Isabel Castrejón Fernández ,&nbsp;Hèctor Corominas ,&nbsp;José A. Gómez Puerta ,&nbsp;Sara Manrique Arija ,&nbsp;Natalia Mena Vázquez ,&nbsp;Ana Ortiz García ,&nbsp;Chamaida Plasencia Rodríguez ,&nbsp;Lucía Silva Fernández ,&nbsp;Jesús Tornero Molina","doi":"10.1016/j.reumae.2024.09.002","DOIUrl":"10.1016/j.reumae.2024.09.002","url":null,"abstract":"<div><h3>Objective</h3><div>To update the consensus document of the Spanish Society of Rheumatology (SER) regarding the use of targeted biological and synthetic therapies in rheumatoid arthritis (RA) with the aim of assisting clinicians in their therapeutic decisions.</div></div><div><h3>Methods</h3><div>A panel of 13 experts was assembled through an open call by SER. We employed a mixed adaptation-elaboration-update methodology starting from the 2015 Consensus Document of the Spanish Society of Rheumatology on the use of biological therapies in RA. Starting with systematic reviews (SR) of recommendations from EULAR 2019, American College of Rheumatology 2021, and GUIPCAR 2017, we updated the search strategies for the PICO questions of GUIPCAR. An additional SR was conducted on demyelinating disease in relation to targeted biological and synthetic therapies. Following the analysis of evidence by different panelists, consensus on the wording and level of agreement for each recommendation was reached in a face-to-face meeting.</div></div><div><h3>Results</h3><div>The panel established 5 general principles and 15 recommendations on the management of RA. These encompassed crucial aspects such as the importance of early treatment, therapeutic goals in RA, monitoring frequency, the use of glucocorticoids, the application of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs. Additionally, recommendations on dose reduction of these drugs in stable patients were included. This update also features recommendations on the use of bDMARDs and Janus Kinase inhibitors in some specific clinical situations, such as patients with lung disease, a history of cancer, heart failure, or demyelinating disease.</div></div><div><h3>Conclusions</h3><div>This update provides recommendations on key aspects in the management of RA using targeted biological and synthetic therapies.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 423-439"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentric reticulohistiocytosis: A 20-year diagnosis beneath the surface","authors":"David Fernández-Fernández ,&nbsp;Ivonne Lourdes Mamani-Velarde ,&nbsp;Maritza Tatiana Segarra-Ortega ,&nbsp;José María Pego-Reigosa","doi":"10.1016/j.reumae.2024.09.008","DOIUrl":"10.1016/j.reumae.2024.09.008","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 456-457"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of psychological interventions to reduce anxiety and depression in patients with lupus. A systematic review and meta-analysis","authors":"Jose Luis Vicente-Escudero","doi":"10.1016/j.reumae.2024.09.006","DOIUrl":"10.1016/j.reumae.2024.09.006","url":null,"abstract":"<div><div>The presence of anxiety and depression symptoms in patients with lupus is common, and some research reports that psychological interventions can reduce them, therefore we conducted a systematic review and meta-analysis of the efficacy of psychological interventions in adults with systemic lupus erythematosus. Randomized and non-randomized clinical trials with adult population diagnosed with lupus, treated with psychological intervention, and compared with similar groups were selected. Several databases were searched in July 2023. Fourteen studies were included in the meta-analysis, with moderate effect sizes for anxiety and depression in group intervention modalities. Factors such as percentage of sample with lupus, gender, medication, and interventions with relaxation components influenced the results. Group psychological intervention programs are effective in reducing symptoms in patients with lupus, although further research on treatment modulating variables is needed.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 440-451"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty assessment in patients with Behçet's syndrome: A cross-sectional monocentric study","authors":"Hakan Apaydin ,&nbsp;Serdar Can Güven ,&nbsp;Rezan Koçak Ulucaköy ,&nbsp;Hakan Babaoğlu ,&nbsp;Esra Kayacan Erdoğan ,&nbsp;Kevser Orhan ,&nbsp;Berkan Armağan","doi":"10.1016/j.reumae.2024.09.005","DOIUrl":"10.1016/j.reumae.2024.09.005","url":null,"abstract":"<div><h3>Aims</h3><div>Evidence evaluating the association between pre-frailty and frailty, and risk of adverse health outcomes in patients with Behçet's syndrome (BS) is limited in the literature. The aim of this study was to characterize the prevalence of frailty and associated factors in a single-centre cohort of patients with BS.</div></div><div><h3>Methods</h3><div>Based on the International Study Group's criteria, this was a monocentric cross-sectional study of BS patients. The Fried frailty criteria were used to define frailty. The Turkish version of the Behçet's Disease Current Activity Form was used to measure the disease activity of BS. Damage index was assessed with the Behçet's Syndrome Overall Damage Index.</div></div><div><h3>Results</h3><div>Forty-four patients were enrolled. According to Fried frailty criteria, patients were classified as 13.6% frail, 59% pre-frail, and 27.2% robust, respectively. Compared to pre-frail and robust patients, frail patients had higher levels of inflammatory markers at the time of diagnosis. CRP levels at time of diagnosis and at the last visit were higher in the frail group than in the pre-frail and robust groups (<em>p</em> <!-->=<!--> <!-->0.039 and <em>p</em> <!-->=<!--> <!-->0.023, respectively). When active drugs for BS were evaluated, systemic glucocorticoid (50%, <em>p</em> <!-->=<!--> <!-->0.030) and cyclophosphamide (33.3%, <em>p</em> <!-->=<!--> <!-->0.006) treatments were higher in the frail group.</div></div><div><h3>Conclusions</h3><div>Frailty and pre-frailty are commonly detected even in younger patients with BS. Inflammation can be described as potential determinants of frailty status.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 409-415"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controversy about the use and financing of SYSADOA for osteoarthritis in Spain: An analysis of the scientific-social debate in the media","authors":"Pedro Alfonso Domínguez Vera ,&nbsp;Luis Carrasco Páez","doi":"10.1016/j.reumae.2024.09.003","DOIUrl":"10.1016/j.reumae.2024.09.003","url":null,"abstract":"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyse the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favour of public funding and use as a treatment for OA patients.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 416-422"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor in response to: “Spontaneous pneumomediastinum: An extra muscular manifestation of anti-MDA5 dermatomyositis. Report of 2 cases”","authors":"Santiago Campbell-Silva ,&nbsp;Iyuleisa Castro-González ,&nbsp;Santiago Campbell-Quintero ,&nbsp;Sebastián Campbell-Quintero","doi":"10.1016/j.reumae.2024.09.001","DOIUrl":"10.1016/j.reumae.2024.09.001","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 8","pages":"Pages 454-455"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How do gene mutation diversity and disease severity scoring affect physical capacity and quality of life in children/adolescents with Familial Mediterranean Fever?","authors":"Elif Gur Kabul ,&nbsp;Merve Bali ,&nbsp;Bilge Basakci Calik ,&nbsp;Zahide Ekici Tekin ,&nbsp;Gulcin Otar Yener ,&nbsp;Selcuk Yuksel","doi":"10.1016/j.reumae.2024.07.005","DOIUrl":"10.1016/j.reumae.2024.07.005","url":null,"abstract":"<div><h3>Objectives</h3><p>The aim of this study is to examine how gene mutation diversity and disease severity affect physical capacity and quality of life in children/adolescents with Familial Mediterranean Fever (FMF).</p></div><div><h3>Methods</h3><p>Eighty children/adolescents (42 female, 38 male) diagnosed with FMF according to Tell-Hashomer diagnostic criteria were included in this study. Disease severity score (PRAS), running speed and agility and strength subtests of Bruininks-Oseretsky Test of Motor Proficiency Second Edition Short Form (BOT-2 SF), Physical Activity Questionnaire, Pediatric Quality of Life Inventory 3.0 Arthritis Module (PedsQL) was used for evaluation. Participants were divided into 2 groups as M694V and other mutations according to MEFV gene mutation and were divided into 3 groups as mild, moderate and severe according to PRAS.</p></div><div><h3>Results</h3><p>When the data were compared between groups; in terms of gene mutation, a significant difference was observed in treatment subtest of PedsQL-parent form in favor of the M694V gene mutation group (<em>p</em> <!-->&lt;<!--> <!-->0.05). In terms of PRAS, significant difference was seen in the pain, treatment subtests and total score of the PedsQL-child form, and in the pain, treatment, worry subtests and total score of the PedsQL-parent form in favor of the mild group (<em>p</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusions</h3><p>MEFV gene mutations in children and adolescents with FMF did not differ on physical capacity and quality of life. PRAS was not effective on physical parameters, but quality of life decreased as the severity score increased. Encouraging children/adolescents with FMF to participate in physical activity and to support them psychosocially can be important to improve their quality of life.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 7","pages":"Pages 360-365"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a core domain set for nailfold capillaroscopy reporting","authors":"Yasser El Miedany ,&nbsp;Sherif Ismail ,&nbsp;Mary Wadie ,&nbsp;Ulf Müller-Ladneru ,&nbsp;Roberto Giacomelli ,&nbsp;Vasiliki Liakouli ,&nbsp;Walter Hermann ,&nbsp;Nihal Fathy ,&nbsp;Maha El Gaafary ,&nbsp;Nermin A. Fouad ,&nbsp;Sally Saber ,&nbsp;Mohamed Hassan Abu-Zaid","doi":"10.1016/j.reumae.2024.07.003","DOIUrl":"10.1016/j.reumae.2024.07.003","url":null,"abstract":"<div><h3>Background</h3><p>The peripheral microangiopathy may be well evaluated and studied by nailfold capillaroscopy (NFC) which is a safe and non-invasive technique. NFC has been reported to have both diagnostic and prognostic values in patients presenting with Raynaud's phenomenon.</p></div><div><h3>Objective</h3><p>The overarching objective of this work was to make a consensus on what domains should be included in a capillaroscopy report and that it can be used in daily clinical practice and clinical research in the area of rheumatology.</p></div><div><h3>Methods</h3><p>A Delphi questionnaire was developed regarding capillaroscopy report from a literature review and expert consensus. The first Delphi round included 14 core areas, its 18 domains with 50 subdomains, derived from a systematic literature review. The level of evidence was determined for each core set using the Oxford Centre for Evidence-based Medicine (CEBM) system. Nine response categories have been set per each item ranging between 1 and 9. Round 2, aimed to reach preliminary consensus “in” or “out” for domains. It included all items that were rated “critical” by at least 80% of the participants as well as any new domains proposed in round 1.</p></div><div><h3>Results</h3><p>The participants to the first, and second round were 11 experts. Fourteen domains were discussed in the two rounds. At the end of the survey, the final report template of NFC in rheumatology reached a consensus.</p></div><div><h3>Conclusion</h3><p>A nailfold capillaroscopy report template has been developed by this study, based on outcomes of a Delphi process, by international participants panel. All domains met the 80% voting threshold set in this work. The reporting template can be used for both clinical research as well as day to day practice to provide guidance and standardize the NFC reporting.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 7","pages":"Pages 345-352"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141998262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management, development and methodology of the Clinical Practice Guidelines and Recommendations of the Spanish Society of Rheumatology","authors":"Petra Díaz del Campo Fontecha ,&nbsp;Noe Brito-García ,&nbsp;Mercedes Guerra-Rodríguez ,&nbsp;Silvia Herrera-López ,&nbsp;Federico Díaz-González","doi":"10.1016/j.reumae.2024.07.010","DOIUrl":"10.1016/j.reumae.2024.07.010","url":null,"abstract":"<div><p>The Spanish Society of Rheumatology (SER) brings together the majority of Spain's rheumatologists and, among the many services it offers its members, has a Research Unit (RU). This unit provides methodological support to SER members in clinical and epidemiological research, coordinates and carries out research projects, designs and maintains large patient databases, develops qualitative research projects and produces evidence-based medicine (EBM) documents. Through this last activity, the RU of the SER produces clinical practice guidelines and recommendation documents on topics relevant to rheumatology that meet the most demanding methodological standards. The aim of this article is to describe the management process and methodology followed by the UI of the SER to identify the topics of its EBM documents and how it executes and develops its guidelines and recommendations.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 7","pages":"Pages 392-397"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction between angiotensin-converting enzyme gene rs4343 polymorphism, environment factors, and angiotensin II level on susceptibility to knee osteoarthritis","authors":"Basma Mohammed Mohammed Ali Elnaggar ,&nbsp;Nashwa Mohamed Abd Elbaky ,&nbsp;Eman Salah Albeltagy ,&nbsp;Hala Mohamed El Zomor","doi":"10.1016/j.reumae.2024.07.007","DOIUrl":"10.1016/j.reumae.2024.07.007","url":null,"abstract":"<div><h3>Objectives</h3><p>Osteoarthritis (OA) is a complex multifactorial disease. The association of knee OA risk with ACE gene rs4343 polymorphism, gene environment synergistic effect, and angiotensin II serum level has not been previously examined. Therefore, we investigate the ACE gene rs4343 polymorphism in knee OA, and its association with severity of knee OA, and angiotensin II serum level.</p></div><div><h3>Methods</h3><p>Using a case–control design, we recruited 200 subjects (100 cases and 100 controls) and all were subjected to genotyping of rs4343 SNP by real-time polymerase chain reaction and assay of serum angiotensin II level by ELISA.</p></div><div><h3>Results</h3><p>G containing genotypes (AG and GG) and G allele frequencies of the ACE rs4343 polymorphism were significantly higher in the case group than that in the control group. There was significant association between ACE rs4343 genotypes and risk of knee OA under the following genetic inheritance models: GG vs. AA (<em>P</em> <!-->=<!--> <!-->0.003), AA vs. GG/AG (<em>P</em> <!-->=<!--> <!-->0.014), AG/AA vs. GG (<em>P</em> <!-->=<!--> <!-->0.037), and G vs. A (<em>P</em> <!-->&lt;<!--> <!-->0.001). Stratified analyses showed ACE rs4343 polymorphism was evidently associated with a significantly increased risk of knee OA among those had BMI<!--> <!-->≥<!--> <!-->25% (adjusted OR<!--> <!-->=<!--> <!-->3.016; 95% CI 1.052–8.648; <em>P</em> <!-->=<!--> <!-->0.040). Additionally, knee OA patients with GG genotype had greater knee specific WOMAC index, Kellgren score, and serum angiotensin II level than those with AA or GA genotypes.</p></div><div><h3>Conclusion</h3><p>The investigated polymorphism in the ACE gene rs4343 may reflect the risk and severity of knee OA in the Egyptian population, particularly with the GG genotype. The interaction between ACE gene rs4343 polymorphism and obesity further increased the risk of knee OA. Moreover, the higher angiotensin II level may be involved in the pathogenesis of knee OA.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 7","pages":"Pages 372-379"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}